Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy

Cornely, 2017, Improving outcome of fungal disease—guiding experts and patients towards excellence, Mycoses, 60, 420, 10.1111/myc.12628 Morgan, 2005, Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program, Med Mycol, 43, S49, 10.1080/13693780400020113 Kontoyiannis, 2010, Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database, Clin Infect Dis, 50, 1091, 10.1086/651263 Ullmann, 2018, Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline, Clin Microbiol Infect, 24, e1, 10.1016/j.cmi.2018.01.002 Patterson, 2016, Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis, 63, e1, 10.1093/cid/ciw326 Eigl, 2017, Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis, Med Mycol, 55, 528 Auberger, 2012, Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study, J Antimicrob Chemother, 67, 2268, 10.1093/jac/dks189 Park, 2011, Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006, Emerg Infect Dis, 17, 1855, 10.3201/eid1710.110087 Nucci, 2014, Improvement in the outcome of invasive fusariosis in the last decade, Clin Microbiol Infect, 20, 580, 10.1111/1469-0691.12409 Cornely, 2014, ESCMID and ECMM joint guidelines for the diagnosis and management of mucormycosis 2013, Clin Microbiol Infect, 20, 5, 10.1111/1469-0691.12371 van Burik, 2006, Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases, Clin Infect Dis, 42, e61, 10.1086/500212 Perkhofer, 2008, Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro, Antimicrob Agents Chemother, 52, 2636, 10.1128/AAC.00492-08 Ibrahim, 2009, Posaconazole mono- or combination therapy for treatment of murine zygomycosis, Antimicrob Agents Chemother, 53, 772, 10.1128/AAC.01124-08 Rodriguez, 2008, Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae, Antimicrob Agents Chemother, 52, 3786, 10.1128/AAC.00628-08 Reed, 2008, Combination polyene–caspofungin treatment of rhino-orbital-cerebral mucormycosis, Clin Infect Dis, 47, 364, 10.1086/589857 Pagano, 2013, Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic disease: a report from the SEIFEM and FUNGISCOPE registries, Haematologica, 98, e127, 10.3324/haematol.2012.083063 Kyvernitakis, 2016, Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis, Clin Microbiol Infect, 22, 10.1016/j.cmi.2016.03.029 Tortorano, 2014, ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others, Clin Microbiol Infect, 20, 27, 10.1111/1469-0691.12465 Guinea, 2008, In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species, Antimicrob Agents Chemother, 52, 1396, 10.1128/AAC.01512-07 Jenks, 2018, Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy, Drug Des Devel Ther, 12, 1033, 10.2147/DDDT.S145545